OncoMatch/Clinical Trials/NCT05543954
68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients
Is NCT05543954 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including 68Ga-FAPI-RGD and 18F-FDG for lung neoplasms.
Treatment: 68Ga-FAPI-RGD · 18F-FDG · 68Ga-FAPI · 68Ga-RGD — Based on the high expression of specific receptors on the surface of diseased tissues and neovascularization, noninvasive targeted molecular imaging can be used to visualize lesions in vitro by combining specific ligands labeled with short half-life isotopes. Lung cancer tissues express fibroblast activating protein FAP, and also have high expression of integrin αVβ3 receptor on the surface of blood vessels. In this study, a novel dual-target imaging agent 68Ga-FAPI-RGD was used for PET/CT imaging of lung cancer.
Check if I qualifyEligibility summary
For patients with Lung Neoplasm.
This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify